The purpose of this first-in-human study is to assess the technical feasibility, deployment characteristics, and safety of the 23mm SJM Transfemoral Transcatheter Heart Valve and delivery system in subjects with severe symptomatic aortic stenosis (AS). This is a single center, prospective, non-randomized, first-in-human investigational study without concurrent or matched controls.
Data will be collected at baseline, procedure, discharge (date of hospital discharge or 7 days post-implant, whichever occurs first), 30 days post implant, 3 months post implant, 6 months post implant, and 12 months post implant.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
10
Placement of the SJM TAVI aortic valve with a transfemoral delivery system.
Royal Victoria Hospital
Belfast, United Kingdom
Assessment of Technical Feasibility and Device Deployment Characteristics
Evaluate the technical feasibility and device deployment characteristics (observed at procedure) by: 1. The ability for the valve to be deployed at the desired location 2. The ability to complete the full procedure 3. Quantification of the time from delivery system entry to a fully deployed and functional valve
Time frame: At time of procedure
Quantification of SAEs Reported (Device Related or Procedure Related)
Evaluate the safety of the 23mm SJM Transcatheter Aortic Heart Valve and transfemoral delivery system by: 1. Summarizing the SAEs observed at procedure that are device or procedure related 2. Summarizing the SAEs observed during the study
Time frame: Through 12 months post implantation
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.